Clinical Trials Directory

Trials / Completed

CompletedNCT05463081

Clinical Trial of "Magic Gyno" Laser Device

Clinical Trial of the Safety and Efficacy of Medical Device "Laser Medical Device "Magic Gyno""

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
70 (actual)
Sponsor
MeLSyTech, Ltd · Industry
Sex
Female
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The aim of this prospective study is investigation of efficiency and safety of medical device "Magic Gyno" in accordance with the stated purpose. To assess the condition of the vaginal walls and vulva before and after laser treatment, the following methods will be used: gynecology examination, vaginal health index, clinical blood test, vaginal flora examination, vaginal pH. International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF), Female Sexual Function Index (FSFI) and The Short Form Health Survey (SF-36) will be used to collect feedback on changes in the participants life quality. Total up to 70 participants with pathology of pelvic organs will be involved in the study. Participants will be divided into two groups: group with genitourinary symptoms and group with vaginal relaxation symptoms, by 35 participants in each. The time intervals between tests will be the same for both groups. The main hypothesis of the study is improvement in condition of the vaginal walls after laser treatment compared with the condition before treatment.

Detailed description

The principle of participant distribution into groups is the character of vaginal walls and vulva pathology. Total up to 70 participants will be involved in the study. Participants will be divided into two groups: group with genitourinary symptoms and group with vaginal relaxation symptoms by 35 participants in each. The types of examination of each group are the same and include: General methods: demographic data determination, vital signs determination, gynecological examination, physical examination, clinical blood analysis with glucose determination, clinical urine test, vaginal smear for flora and oncocytology, pelvic ultrasound. Special methods: vaginal smear for flora, vaginal pH determination, filling out the questionnaire (Female Sexual Function Index, International Consultation on Incontinence Questionnaire - Short Form, The Short Form Health Survey), Vaginal Health Index determination. The treatment procedure of this study is the laser treatment of the vagina and vulva with a "Magic Gyno" laser with subsequent monitoring. Treatment Technique: Laser treatment procedure will be carried out in three stages. In total, three procedures will be performed with an interval of 4-6 weeks. One follow-up visit will follow: 90 days after the last procedure. During the procedure, the following sequence of actions will be performed: 1. st Stage - vaginal processing with a conical mirror handpiece, 2. nd Stage - vaginal processing with a corner mirror handpiece, 3. rd Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece. Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 nanoseconds (ns), the pause between pulses is 30 microseconds (us). The energy of one pulse is about 1 millijoule (mJ). The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth. Participants of all groups will be tested with the general methods necessary to include the participant in the study at the first visit. For both group: Studies will be carried out using special methods and then laser treatment of the vagina and vulva and paraurethral region will be performed during the 2nd, 3d, and 4th visits. Studies with all special methods will be performed during the 1st (to include participant in the study), 2nd (before the first treatment), 4th (before the last treatment) and 5th (90 days after the last treatment) visits. Thus, direct comparison between participants condition before and 90 days after treatment within each group will be carried out. The study will be carried out with the participation of Tver State Medical Academy. All data obtained during the study will be transferred to the manufacturer of "MeLSyTech" Ltd. The study will be monitored by "MeLSyTech" Ltd as follows: In the start of study to ensure awareness of researchers about the plan, the rules for filling in case research forms, work with the device. Once a 3 month, monitoring of provided documents (copies of individual registration records of participants (case research forms), informed consent, test results) for the complete filling of the forms; the clarity of filling out forms, the possibility of systematizing information from the forms of their assessment. Monitoring will be conducted with a coordinator visit of the research center and analysis activities, such as participants recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. In the end of study monitoring will be conducted with a coordinator visit of the research center and analysis activities, such as participants recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. The investigator submits a clinical evaluation report to the sponsor. Statistics The analysis will be carried out within groups at different time intervals (analysis of matched groups). Before performing statistical analysis of the data, the distribution type of the variables will be assessed. To assess the normality of distribution for each variable, histograms of frequency distributions will be visually evaluated, indicators of skewness, kurtosis, and the D'Agostino-Pearson normality test will be used. In addition to checking the type of distribution of variables, the equality of variances of the studied groups will be assessed using the methods of analysis of variance, in particular the Brown-Forsythe test. Methods of descriptive analysis will be used depending on the type of distribution of the variable. With a normal distribution, the mean (M) and standard deviation (SD) will be calculated. In case of an nongaussian distribution, the median (Me) and interquartile range will be calculated. Different algorithms of statistical analysis will be applied depending on the type of distribution of variables. Comparison of the paired groups with a normal distribution, in case of the equality of the variances, will be carried out by the methods of analysis of variance ANOVA. Comparison of groups in pairs will be performed using the post-hoc method of posterior multiple comparisons (Tukey test). Comparison of groups in which variables do not follow the normal distribution will be carried out using the methods of nonparametric analysis of variations: the Friedman test for matched groups. Differences will be considered statistically significant if the significance P values are \<0.05.

Conditions

Interventions

TypeNameDescription
DEVICELaser treatmentLaser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ. General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s. The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth.
DIAGNOSTIC_TESTBlood testTaking blood from a vein for Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study) and clinical blood analysis (to include the participant in the study and evaluate procedure efficiency)
DIAGNOSTIC_TESTClinical urine testUrine sampling for Clinical urine test (to include the participant in the study).
DIAGNOSTIC_TESTVaginal smearVaginal smear for flora investigation (to include the participant in the study and evaluate procedure efficiency)
DIAGNOSTIC_TESTPelvic ultrasoundPelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
OTHERFemale Sexual Function IndexFemale Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
OTHERInternational Consultation on Incontinence Questionnaire - Short FormInternational Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
OTHERThe Short Form Health SurveyThe Short Form Health Survey will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
DIAGNOSTIC_TESTVaginal Health IndexVaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
DIAGNOSTIC_TESTVital signs determinationVital signs determination (respiration rate, blood pressure, pulse rate, body temperature).
DIAGNOSTIC_TESTpH of vagina determinationPotential of hydrogen (pH) of vagina will be investigated by test-lines paper (to evaluate procedure efficiency).
DIAGNOSTIC_TESTPhysical parameters determinationPhysical parameters determination (body weight, age, height, body mass index).

Timeline

Start date
2022-08-05
Primary completion
2024-01-22
Completion
2024-01-22
First posted
2022-07-18
Last updated
2024-12-10

Locations

1 site across 1 country: Russia

Source: ClinicalTrials.gov record NCT05463081. Inclusion in this directory is not an endorsement.